BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has Been Awarded To Date Under The Contract

By: via Benzinga
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.